Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Laurie H Sehn, MD, Marek Trněný, MD, Kamal Bouabdallah, MD, Gregory Dueck, MD, John G. Gribben, MD DSc, P.J. Lugtenburg, MD PhD, Gilles A. Salles, MD PhD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Wenxin Liu, PhD, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2822.

https://doi.org/10.1182/blood-2019-123422

Published: 2019

Journal Articles

Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907

Daniel J. Landsburg, MD, Rod Ramchandren, MD, Yasuhiro Oki, MD, John M. Pagel, MD PhD, P.J. Lugtenburg, MD PhD, Robert Gharavi, PharmD, Anna Ma, MS, Amir Hafeez, MD, Stefan Klaus Barta, MDMRCP,MS

Blood (2017) 130 (Supplement 1): 1555.

https://doi.org/10.1182/blood.V130.Suppl_1.1555.1555

Published: 2017

Journal Articles

Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.

Antonio Salar, MD, PhD, Corinne Haioun, MD, Francesca Gaia Rossi, MD, Ulrich Duehrsen, MD, Ruth Pettengell, Hans Erik Johnsen, MD, Ulrich Jaeger, MD, Gregor Verhoef, Matthias Schwenkglenks, PhD, Fernando Principe, MD, Pamela Bacon, PhD, Kate Bendall, P.J. Lugtenburg, MD, PhD

Blood (2009) 114 (22): 107.

https://doi.org/10.1182/blood.V114.22.107.107

Published: 2009

Journal Articles

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.

J.C. Kluin-Nelemans, MD, PhD, Marinus Van Marwijk Kooij, MD, PhD, P.J. Lugtenburg, MD, PhD, Pierre W Wijermans, Willem JL Van Putten, MSc, Gustaaf W van Imhoff, MD, PhD

Blood (2008) 112 (11): 1999.

https://doi.org/10.1182/blood.V112.11.1999.1999

Published: 2008

Journal Articles

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Pieter Sonneveld, MD, Wim van Putten, MsC, Douwe Biesma, MD, Harald Holte, MD, Marinus van Marwijk Kooij, MD, Mark Henri H. Kramer, MD, P.W. Wijermans, MD, Monique Steijaert, Gustaaf W. van Imhoff, MD, P.J. Lugtenburg, MD, P.C. Huijgens, MD, Mikael Eriksson, MD

Blood (2006) 108 (11): 210.

https://doi.org/10.1182/blood.V108.11.210.210

Published: 2006

NARROW

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907

Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Email alerts

ASH Publications

American Society of Hematology

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907

Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only